Dr. Sammons is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800Fax+1 617-632-1930
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2012
Certifications & Licensure
MA State Medical License 2022 - 2025
NC State Medical License 2015 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib Start of enrollment: 2023 Mar 23
Roles: Contact
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Roles: Contact
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Start of enrollment: 2023 Dec 26
Roles: Sponsor-Investigator, Principal Investigator, Contact
Publications & Presentations
PubMed
- 28 citationsPreclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E D Van Swearingen
Clinical Cancer Research. 2023-01-04 - 22 citationsEarly Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.Jeremy Force, Lynn Howie, Sara Abbott, Rex C. Bentley, P. Kelly Marcom
Clinical Breast Cancer. 2018-10-01 - 10 citationsTumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.Romualdo Barroso-Sousa, Jana Priscila Pacífico, Sarah Sammons, Sara M Tolaney
Cancers. 2023-08-07
Press Mentions
Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast CancerAugust 5th, 2023- CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast CancerSeptember 9th, 2023
- New Approaches in the Treatment of HR+ Metastatic Breast CancerJuly 11th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
